Cite
HARVARD Citation
Michael, M. et al. (n.d.). Multicenter randomized, open‐label phase II trial of sequential erlotinib and gemcitabine compared with gemcitabine monotherapy as first‐line therapy in elderly or ECOG PS two patients with advanced NSCLC. Asia-Pacific journal of clinical oncology. 11 (1), pp. 4-14. [Online].